intedanib for IPF patients with resected NSCLC in JAPAN Phase 2 study - NINJA P-2 study

Okada Morihito0 个研究点目标入组 30 人开始时间: 2022年10月20日最近更新: 2024年4月1日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 20age old 至 ot applicable（—）
性别: All

入选标准

•1. who are at least 20 years of age at the time of consent
•2. meet the diagnostic criteria for IPF (attached) within 1 year of incorporation and all of the following
•(1) High-resolution CT findings or pathological findings are determined to be either UIP pattern, Probable UIP pattern, or Indeterminate for UIP pattern based on the ATS/ERS/JRS/ALAT 2018 International Classification11 (must be documented in either the radiology report, histopathology report, or medical record). (This must be noted in either the radiology report, histopathology report, or medical record).
•The patient does not have interstitial lung disease (ILD) with an obvious cause such as collagen disease, drug-induced, sarcoidosis, hypersensitivity pneumonitis, etc. The diagnosis of idiopathic pulmonary fibrosis (IPF) should be made comprehensively by a radiologist, a respiratory physician, and a pathologist.
•Central judgment of imaging and pathology in the diagnosis of IPF
•In this study, the diagnosis of idiopathic pulmonary fibrosis (IPF) will be made based on preoperative high-resolution CT findings and histopathological findings of lung resection specimens. Because the diagnosis of idiopathic pulmonary fibrosis (IPF) is difficult and some variation in institutional diagnosis can be expected, it was decided to perform a central determination of imaging and pathology. The items for central determination include the diagnosis of idiopathic pulmonary fibrosis (IPF) (IPF/IPF(Likely)/Indeterminate/Non-IPF) using the lung fields of high-resolution CT and the background lungs of pathology specimens. For the above items, the percentage of agreement between the institutional judgment and the central judgment will be examined. This will be done in accordance with the Central Judgment Procedure.
•3. Patients with a diagnosis of stage 1-3 non-small cell lung cancer based on clinical and pathological diagnosis after pneumonectomy.
•4. have pathologically confirmed complete resection (R0) in the surgically resected specimen.
•Complete resection is defined as grossly and histologically complete resection of lung cancer. If there is histological evidence of residual cancer, it is incomplete resection.
•5. No serious adverse events (Grade 3 or higher by CTCAE criteria or acute exacerbation of interstitial pneumonia) within 30 days after lung resection.
•6. patients with Grade 1-2 adverse events by CTCAE criteria within 30 days of pneumonectomy, if, in the judgment of the treating physician, participation in the study would not be detrimental to the patient.
•7. performance status (PS) is 0 or 1 according to ECOG criteria. (PS must be documented in the medical record)
•8.No prior chemotherapy within 2 years, including other types of cancer. Perioperative chemotherapy for curatively resected non-small cell lung cancer is not actively recommended, but may be administered and is not an exclusion criterion.
•9. latest laboratory values within 30 days prior to enrollment (the same day of the week 4 weeks prior to the date of enrollment is acceptable) meet all of the following
•(1) White blood cell count > 3,000 /mm3 (2) Hemoglobin > 10.0 g/dL (3) Platelet count > 15 x 104 /mm3
•No ischemic changes on the latest 12-lead ECG at rest within 60 days prior to enrollment. However, if ischemic changes are detected on 12-lead EKG, the patient will be considered eligible if it is determined that treatment for ischemic heart disease is not necessary after performing echocardiography, exercise stress EK

排除标准

•1, Patients with elevated AST or ALT or total bilirubin >1.5x ULN.
•2, Patients with renal disease (serum Cr > 1.5 mg/dL or CKD stage 3 or higher).
•3, Patients with the following complications.
•3, Patients with the following complications: hepatic disease, psychiatric disease, seizure or paroxysmal disorder, history or predisposition to thromboembolism, and patients receiving anticoagulant therapy.
•4, Patients with a history of serious adverse reactions to nintedanib.
•5, Patients who meet any of the contraindications to the administration of nintedanib.
•6, Pregnant and lactating women, women who may be pregnant, or women who wish to have a baby.
•7, Patients who have received anti-fibrotic drugs within 60 days prior to enrollment.
•8, Patients who are deemed to interfere with, limit, or confound the evaluation specific to the clinical research protocol.
•9, Employees of the Principal Investigator or other investigators or the site of the study who are directly involved in this or other clinical research, or family members of such employees or Principal Investigators.

研究者

发起方

Okada Morihito

相似试验

招募中

不适用

intedanib treatment for the patients with systemic scleroderma-associated interstitial lung disease-a prospective observational study

JPRN-UMIN000039605Department of Respiratory Medicine, Juntendo University Hospital100

招募中

不适用

Efficacy and Safety of Nintedanib in Idiopathic Pleuroparenchymal Fibroelastosis (Phase 2 trial)Idiopathic pleuroparenchymal fibroelastosis

JPRN-UMIN000042946Department of Respiratory Medicine and Rheumatology Graduate School of Biomedical Sciences Tokushima University10

已完成

3 期

Japanese Intergroup Study of Nintedanib for NSCLC with IPFAdvanced Non-small cell lung cancer with idiopathic pulmonary fibrosis

JPRN-jRCTs071180049Okamoto Isamu243

进行中（未招募）

不适用

Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial - INFASTModerate-to-severe active axial spondyloarthritisMedDRA version: 9.1Level: LLTClassification code 10058338Term: Spondylarthritis

EUCTR2008-000982-51-DKSchering-Plough Research Institute, a Division of Schering Corporation150

进行中（未招募）

1 期

EUCTR2008-000982-51-BESchering-Plough Research Institute, a Division of Schering Corporation150